However, although CD3/CD19 BiTE blinatumomab is currently approved by the FDA for the treatment of acute lymphoblastic leukemia [92], clinical trials have shown that serious side effects may occur [93]. Here, CD19 is linked to acute lymphoblastic leukemia.